Interferons and interleukin-2

Molecular basis of activity and therapeutic results

Thomas E. Hutson, Snehal Thakkar, Peter A Cohen, Ernest C. Borden

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Metastatic renal cell carcinoma (RCC) is a tumor refractory to standard cytotoxic chemotherapy regimens. The rationale for the use of cytokines in this cancer is based upon compelling evidence that RCC is sensitive to immunological manipulation. Cytokine-based therapy with either interleukin-2 (IL-2) or interferon-α (IFN-α) can result in objective tumor responses in up to 15% of patients, and in selected patients, these responses may be durable. Subsequently these cytokines have impacted positively on both quality and quantity of life for thousands of RCC patients - and it seems probable that their full clinical potential has yet to be reached. The development of targeted therapies for clear cell RCC with the potential for greater antitumor activity and less toxicity has brought into question the role of cytokines in this patient population. However, no noncytokine therapy to date has proven curative in patients with metastatic RCC. A series of recently completed and ongoing clinical trials will partially define the future role of IFNs and IL-2 in sequence and in combination with newer targeted agents. As the knowledge of the role that IFN and IL-2 contribute to both innate and acquired immunity continues to expand, it seems probable that the structure and/or application of these cytokines will be further modulated for therapeutic advantage in RCC.

Original languageEnglish (US)
Title of host publicationRenal Cell Carcinoma: Molecular Targets and Clinical Applications
PublisherHumana Press
Pages49-78
Number of pages30
ISBN (Print)9781588297372
DOIs
StatePublished - 2009

Fingerprint

Renal Cell Carcinoma
Interferons
Interleukin-2
Cytokines
Therapeutics
Neoplasms
Adaptive Immunity
Innate Immunity
Quality of Life
Clinical Trials
Drug Therapy
Population

Keywords

  • Angiogenesis inhibition
  • Clinical effects of IL-2 and IFN
  • IFN-α2, IL-2
  • Interleukin
  • Nterferon

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hutson, T. E., Thakkar, S., Cohen, P. A., & Borden, E. C. (2009). Interferons and interleukin-2: Molecular basis of activity and therapeutic results. In Renal Cell Carcinoma: Molecular Targets and Clinical Applications (pp. 49-78). Humana Press. https://doi.org/10.1007/978-1-59745-332-5_4

Interferons and interleukin-2 : Molecular basis of activity and therapeutic results. / Hutson, Thomas E.; Thakkar, Snehal; Cohen, Peter A; Borden, Ernest C.

Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press, 2009. p. 49-78.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hutson, TE, Thakkar, S, Cohen, PA & Borden, EC 2009, Interferons and interleukin-2: Molecular basis of activity and therapeutic results. in Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press, pp. 49-78. https://doi.org/10.1007/978-1-59745-332-5_4
Hutson TE, Thakkar S, Cohen PA, Borden EC. Interferons and interleukin-2: Molecular basis of activity and therapeutic results. In Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press. 2009. p. 49-78 https://doi.org/10.1007/978-1-59745-332-5_4
Hutson, Thomas E. ; Thakkar, Snehal ; Cohen, Peter A ; Borden, Ernest C. / Interferons and interleukin-2 : Molecular basis of activity and therapeutic results. Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press, 2009. pp. 49-78
@inbook{3a9ca497e2f349c2ae3fe292b3346273,
title = "Interferons and interleukin-2: Molecular basis of activity and therapeutic results",
abstract = "Metastatic renal cell carcinoma (RCC) is a tumor refractory to standard cytotoxic chemotherapy regimens. The rationale for the use of cytokines in this cancer is based upon compelling evidence that RCC is sensitive to immunological manipulation. Cytokine-based therapy with either interleukin-2 (IL-2) or interferon-α (IFN-α) can result in objective tumor responses in up to 15{\%} of patients, and in selected patients, these responses may be durable. Subsequently these cytokines have impacted positively on both quality and quantity of life for thousands of RCC patients - and it seems probable that their full clinical potential has yet to be reached. The development of targeted therapies for clear cell RCC with the potential for greater antitumor activity and less toxicity has brought into question the role of cytokines in this patient population. However, no noncytokine therapy to date has proven curative in patients with metastatic RCC. A series of recently completed and ongoing clinical trials will partially define the future role of IFNs and IL-2 in sequence and in combination with newer targeted agents. As the knowledge of the role that IFN and IL-2 contribute to both innate and acquired immunity continues to expand, it seems probable that the structure and/or application of these cytokines will be further modulated for therapeutic advantage in RCC.",
keywords = "Angiogenesis inhibition, Clinical effects of IL-2 and IFN, IFN-α2, IL-2, Interleukin, Nterferon",
author = "Hutson, {Thomas E.} and Snehal Thakkar and Cohen, {Peter A} and Borden, {Ernest C.}",
year = "2009",
doi = "10.1007/978-1-59745-332-5_4",
language = "English (US)",
isbn = "9781588297372",
pages = "49--78",
booktitle = "Renal Cell Carcinoma: Molecular Targets and Clinical Applications",
publisher = "Humana Press",

}

TY - CHAP

T1 - Interferons and interleukin-2

T2 - Molecular basis of activity and therapeutic results

AU - Hutson, Thomas E.

AU - Thakkar, Snehal

AU - Cohen, Peter A

AU - Borden, Ernest C.

PY - 2009

Y1 - 2009

N2 - Metastatic renal cell carcinoma (RCC) is a tumor refractory to standard cytotoxic chemotherapy regimens. The rationale for the use of cytokines in this cancer is based upon compelling evidence that RCC is sensitive to immunological manipulation. Cytokine-based therapy with either interleukin-2 (IL-2) or interferon-α (IFN-α) can result in objective tumor responses in up to 15% of patients, and in selected patients, these responses may be durable. Subsequently these cytokines have impacted positively on both quality and quantity of life for thousands of RCC patients - and it seems probable that their full clinical potential has yet to be reached. The development of targeted therapies for clear cell RCC with the potential for greater antitumor activity and less toxicity has brought into question the role of cytokines in this patient population. However, no noncytokine therapy to date has proven curative in patients with metastatic RCC. A series of recently completed and ongoing clinical trials will partially define the future role of IFNs and IL-2 in sequence and in combination with newer targeted agents. As the knowledge of the role that IFN and IL-2 contribute to both innate and acquired immunity continues to expand, it seems probable that the structure and/or application of these cytokines will be further modulated for therapeutic advantage in RCC.

AB - Metastatic renal cell carcinoma (RCC) is a tumor refractory to standard cytotoxic chemotherapy regimens. The rationale for the use of cytokines in this cancer is based upon compelling evidence that RCC is sensitive to immunological manipulation. Cytokine-based therapy with either interleukin-2 (IL-2) or interferon-α (IFN-α) can result in objective tumor responses in up to 15% of patients, and in selected patients, these responses may be durable. Subsequently these cytokines have impacted positively on both quality and quantity of life for thousands of RCC patients - and it seems probable that their full clinical potential has yet to be reached. The development of targeted therapies for clear cell RCC with the potential for greater antitumor activity and less toxicity has brought into question the role of cytokines in this patient population. However, no noncytokine therapy to date has proven curative in patients with metastatic RCC. A series of recently completed and ongoing clinical trials will partially define the future role of IFNs and IL-2 in sequence and in combination with newer targeted agents. As the knowledge of the role that IFN and IL-2 contribute to both innate and acquired immunity continues to expand, it seems probable that the structure and/or application of these cytokines will be further modulated for therapeutic advantage in RCC.

KW - Angiogenesis inhibition

KW - Clinical effects of IL-2 and IFN

KW - IFN-α2, IL-2

KW - Interleukin

KW - Nterferon

UR - http://www.scopus.com/inward/record.url?scp=84892110258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892110258&partnerID=8YFLogxK

U2 - 10.1007/978-1-59745-332-5_4

DO - 10.1007/978-1-59745-332-5_4

M3 - Chapter

SN - 9781588297372

SP - 49

EP - 78

BT - Renal Cell Carcinoma: Molecular Targets and Clinical Applications

PB - Humana Press

ER -